Welcome international healthcare professionals

Welcome, this website is intended for healthcare professionals with an interest in the ECC Webcasts. By clicking the button below you are declaring and confirming that you are a healthcare professional.

Date: Mon. 28 Sept / 13:00 – 14:30 / Hall A4

Treatments for BRAF V600-mutant melanoma have changed dramatically including the development of combination therapies which target both BRAF and MEK. This session explores the potential benefits of dual BRAF/MEK inhibition combination therapy targeting both the oncologic driver and a downstream signalling component within the MAPK pathway through a review of the clinical evidence and real-world data as well as an exploration of patient case studies.

This Webcast and Webcast Report were supported by Novartis Oncology, all items are subject to independent peer and editorial review.

Presentations

C. Hoeller (Austria)

Christoph Hoeller tells the story leading up to today’s treatment of BRAF V600E melanoma. He talks about the incidence and treatment of melanoma, the role of the BRAF mutation and the results of clinical trials.

C. Robert (France)

Caroline Robert provides an overview of key clinical studies for BRAF/MEK inhibitor combination therapy in metastatic melanoma, with some late results of the Phase II trial with dabrafenib and trametinib.